IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
+13.69%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$849M
AUM Growth
+$849M
(-15%)
Cap. Flow
-$210M
Cap. Flow
% of AUM
-24.68%
Top 10 Holdings %
Top 10 Hldgs %
53.19%
Holding
100
New
29
Increased
13
Reduced
14
Closed
35
Top Buys
| 1 |
Inspire Medical Systems
INSP
|
$33.8M |
| 2 |
Medtronic
MDT
|
$27M |
| 3 |
Cooper Companies
COO
|
$12.1M |
| 4 |
Fresenius Medical Care
FMS
|
$9.59M |
| 5 |
Bristol-Myers Squibb
BMY
|
$9.05M |
Top Sells
| 1 |
Elevance Health
ELV
|
$43.3M |
| 2 |
Humana
HUM
|
$28M |
| 3 |
Universal Health Services
UHS
|
$24M |
| 4 |
Becton Dickinson
BDX
|
$17.5M |
| 5 |
Cigna
CI
|
$16.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Insmed
INSM
$28.8B
| $106M | 11.91% | 1,450,000 -100,000 | -6% | -$7.3M |
|
2
Tenet Healthcare
THC
$16.3B
| $88.1M | 9.91% | 530,000 +30,000 | +6% | +$4.99M |
|
3
Boston Scientific
BSX
$156B
| $46.1M | 5.19% | 550,000 -100,000 | -15% | -$8.38M |
|
4
Cytokinetics
CYTK
$4.23B
| $39.6M | 4.46% | 750,000 -250,000 | -25% | -$13.2M |
|
|
LBPH
5
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $35M | 3.94% | 1,050,000 -50,000 | -5% | -$1.67M |
|
|
6
Inspire Medical Systems
INSP
$2.77B
| $33.8M | 3.8% | +160,000 | New | +$33.8M |
|
|
7
Medtronic
MDT
$119B
| $27M | 3.04% | +300,000 | New | +$27M |
|
|
BPMC
8
DELISTED
Blueprint Medicines
BPMC
| $26.8M | 3.02% | 290,000 -50,000 | -15% | -$4.63M |
|
9
Encompass Health
EHC
$12.3B
| $26.6M | 2.99% | 275,000 -25,000 | -8% | -$2.42M |
|
10
Novartis
NVS
$245B
| $23M | 2.59% | 200,000 -100,000 | -33% | -$11.5M |
|
11
Arcellx
ACLX
$3.85B
| $23M | 2.58% | 275,000 | – | – |
|
12
Merck
MRK
$210B
| $22.7M | 2.56% | 200,000 -35,000 | -15% | -$3.97M |
|
13
Vera Therapeutics
VERA
$1.38B
| $22.1M | 2.49% | 500,000 | – | – |
|
14
Quest Diagnostics
DGX
$20.3B
| $18.6M | 2.1% | 120,000 +20,000 | +20% | +$3.11M |
|
|
NARI
15
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $16.5M | 1.86% | 400,000 | – | – |
|
16
Revolution Medicines
RVMD
$7.1B
| $15.9M | 1.79% | 350,000 +25,000 | +8% | +$1.13M |
|
17
Crinetics Pharmaceuticals
CRNX
$2.92B
| $15.3M | 1.72% | 300,000 -100,000 | -25% | -$5.11M |
|
18
Regenxbio
RGNX
$451M
| $13.4M | 1.5% | 1,275,000 +325,000 | +34% | +$3.41M |
|
19
Tarsus Pharmaceuticals
TARS
$2.47B
| $12.3M | 1.39% | 375,000 -215,000 | -36% | -$7.07M |
|
|
20
Cooper Companies
COO
$13.4B
| $12.1M | 1.37% | +110,000 | New | +$12.1M |
|
21
Keros Therapeutics
KROS
$618M
| $11.6M | 1.31% | 200,000 +115,000 | +135% | +$6.68M |
|
22
MoonLake Immunotherapeutics
MLTX
$3.54B
| $11.1M | 1.25% | 220,000 | – | – |
|
|
23
Fresenius Medical Care
FMS
$15.1B
| $9.59M | 1.08% | +450,000 | New | +$9.59M |
|
24
Bruker
BRKR
$5.16B
| $9.32M | 1.05% | 135,000 +5,000 | +4% | +$345K |
|
|
25
Bristol-Myers Squibb
BMY
$96B
| $9.05M | 1.02% | +175,000 | New | +$9.05M |
|